Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 4Paraganglioma 4Adrenocortical Carcinoma 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Neoplasm Metastasis 2Adenoma, Islet Cell 2Vulvar Neoplasms 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1Non functioning pancreatic endocrine tumor 1Neurofibrosarcoma 1Nasopharyngeal Carcinoma 1Multiple Sclerosis 1Mouth Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Melanoma 1

Interventions

veliparib 1cabozantinib 1X-Rays 1Temozolomide 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × Specimen Handling × Endocrine × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡